Atezolizumab u liječenju metastatskog raka urotela : retrospektivna analiza : iskustva u Klinici za onkologiju i radioterapiju u Splitu

Komić, Dubravka

prikaz prve stranice dokumenta Atezolizumab u liječenju metastatskog raka urotela : retrospektivna analiza : iskustva u Klinici za onkologiju i radioterapiju u Splitu

master's thesis

Atezolizumab u liječenju metastatskog raka urotela : retrospektivna analiza : iskustva u Klinici za onkologiju i radioterapiju u Splitu

2022. urn:nbn:hr:171:597793

Komić, Dubravka

University of Split
School of Medicine

Cite this document

APA 6th Edition

Komić, D. (2022). Atezolizumab u liječenju metastatskog raka urotela : retrospektivna analiza : iskustva u Klinici za onkologiju i radioterapiju u Splitu (Master's thesis). Split: University of Split, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:597793

MLA 8th Edition

Komić, Dubravka. "Atezolizumab u liječenju metastatskog raka urotela : retrospektivna analiza : iskustva u Klinici za onkologiju i radioterapiju u Splitu." Master's thesis, University of Split, School of Medicine, 2022. https://urn.nsk.hr/urn:nbn:hr:171:597793

Chicago 17th Edition

Harvard

Komić, D. (2022). 'Atezolizumab u liječenju metastatskog raka urotela : retrospektivna analiza : iskustva u Klinici za onkologiju i radioterapiju u Splitu', Master's thesis, University of Split, School of Medicine, accessed 25 April 2024, https://urn.nsk.hr/urn:nbn:hr:171:597793

Vancouver

Komić D. Atezolizumab u liječenju metastatskog raka urotela : retrospektivna analiza : iskustva u Klinici za onkologiju i radioterapiju u Splitu [Master's thesis]. Split: University of Split, School of Medicine; 2022 [cited 2024 April 25] Available at: https://urn.nsk.hr/urn:nbn:hr:171:597793

IEEE

D. Komić, "Atezolizumab u liječenju metastatskog raka urotela : retrospektivna analiza : iskustva u Klinici za onkologiju i radioterapiju u Splitu", Master's thesis, University of Split, School of Medicine, Split, 2022. Available at: https://urn.nsk.hr/urn:nbn:hr:171:597793

Cite this item: https://urn.nsk.hr/urn:nbn:hr:171:597793

Please login to the repository to save this object to your list.

Metadata

Title	Atezolizumab u liječenju metastatskog raka urotela : retrospektivna analiza : iskustva u Klinici za onkologiju i radioterapiju u Splitu
Title (english)	Atezolizumab in patients with metastatic urothelial cancer : retrospective analysis of the treatment experience at the Oncology and Radiotherapy Clinic, University Hospital of Split
Author	Dubravka Komić
Mentor	Tomislav Omrčen (mentor)
Committee member	Snježana Tomić (predsjednik povjerenstva)
Committee member	Branka Petrić Miše (član povjerenstva)
Committee member	Renata Pecotić (član povjerenstva)
Granter	University of Split School of Medicine Split
Defense date and country	2022, Croatia
Scientific / art field, discipline and subdiscipline	BIOMEDICINE AND HEALTHCARE Clinical Medical Sciences Oncology
Abstract	Ciljevi: Primarni ciljevi istraživanja su bili preživljenje bez progresije bolesti (PFS) i ukupno preživljenje (OS) nakon liječenja atezolizumabom u drugoj liniji liječenja metastatskog raka urotela. Ispitanici i postupci: Retrospektivno je analizirano 26 bolesnika koji su započeli drugolinijsko liječenje atezolizumabom metastatskog raka urotela u Klinici za onkologiju i radioterapiju KBC-a Split prije 1. siječnja 2022. Praćeni su u razdoblju od 1. siječnja do 1. listopada 2022. Rezultati: Rezultati naše retrospektivne studije pokazali su da liječenje atezolizumabom u drugoj liniji metastatskog raka urotela produljuje preživljenje. Medijan OS je iznosio 16, 2 mjeseca, te je tako bio veći od medijana OS studija IMvigor210 i IMvigor 211, koji su iznosili 7,9 i 10,6 mjeseci. Naš medijan PFS je iznosio 6,7 mjeseci te je opet bio veći od medijana PFS u studiji IMvigor210 koji je iznosio 2,1 mjeseci. Učestalost nuspojava stupnja 3 i 4 kod naših bolesnika iznosila je 15 % i usporediva je s učestalošću istih u IMvigor210 studiji gdje je iznosila 16%. Zaključci: Liječenje atezolizumabom u drugoj liniji liječenja metastatskog raka urotela produljuje OS, PFS i ima prihvatljiv profil toksičnosti.
Abstract (english)	Objectives: The primary objectives of the analysis were overall survival (OS) and progression-free survival (PFS) for atezolizumab in second-line treatment of metastatic urothelial cancer. Subjects and methods: The records of 26 patients with metastatic urothelial cancer, who started atezolizumab second-line treatment at the Oncology and Radiotherapy Clinic of the University Hospital of Split prior to January 1st 2022, were analysed. Results: Atezolizumab in second-line treatment of metastatic urothelial cancer showed an improvement in overall survival. The median OS was 16,2 months and it exceeded those reported in the IMvigor210 Trial (OS 7,9 months) and the IMvigor211 Trial (OS 10,6 months). The median PFS was 6,7 months, which also exceeded the median PFS reported in the IMvigor210 Trial (PFS 2,1 months). Grade 3 and 4 adverse events occurred in 15 % of patients. That result is comparable to the frequency of grade 3 and 4 adverse events of 16 % that was reported in the IMvigor210 Trial. Conclusions: Atezolizumab in second-line treatment of metastatic urothelial cancer improves overall survival, progression-free survival and has an acceptable toxicity profile.
Keywords
Keywords (english)
Language	croatian
URN:NBN	urn:nbn:hr:171:597793
Study programme	Title: Medicine Study programme type: university Study level: integrated undergraduate and graduate Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resource	Text
File origin	Born digital
Access conditions	Open access
Terms of use
Created on	2022-12-01 12:22:09